DE2202441B2 - Barbitursäureantigene und spezifische Antikörper hierfür - Google Patents

Barbitursäureantigene und spezifische Antikörper hierfür

Info

Publication number
DE2202441B2
DE2202441B2 DE2202441A DE2202441A DE2202441B2 DE 2202441 B2 DE2202441 B2 DE 2202441B2 DE 2202441 A DE2202441 A DE 2202441A DE 2202441 A DE2202441 A DE 2202441A DE 2202441 B2 DE2202441 B2 DE 2202441B2
Authority
DE
Germany
Prior art keywords
substituted
barbituric acid
acid derivative
protein
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE2202441A
Other languages
German (de)
English (en)
Other versions
DE2202441A1 (de
DE2202441C3 (OSRAM
Inventor
Sidney Livingstone N.J. Spector (V.St.A.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE2202441A1 publication Critical patent/DE2202441A1/de
Publication of DE2202441B2 publication Critical patent/DE2202441B2/de
Application granted granted Critical
Publication of DE2202441C3 publication Critical patent/DE2202441C3/de
Granted legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/823—Immunogenic carrier or carrier per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE2202441A 1971-08-24 1972-01-19 Barbitursäureantigene und spezifische Antikörper hierfür Granted DE2202441B2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17451771A 1971-08-24 1971-08-24

Publications (3)

Publication Number Publication Date
DE2202441A1 DE2202441A1 (de) 1973-03-01
DE2202441B2 true DE2202441B2 (de) 1980-04-10
DE2202441C3 DE2202441C3 (OSRAM) 1981-01-15

Family

ID=22636461

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2202441A Granted DE2202441B2 (de) 1971-08-24 1972-01-19 Barbitursäureantigene und spezifische Antikörper hierfür

Country Status (5)

Country Link
US (1) US3766162A (OSRAM)
JP (1) JPS5928864B2 (OSRAM)
CA (1) CA956889A (OSRAM)
DE (1) DE2202441B2 (OSRAM)
GB (1) GB1327545A (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL171930C (nl) * 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3995021A (en) * 1972-05-15 1976-11-30 Biological Developments, Inc. Antigens of 5,5'alkylphenyl barbituric acids and related hydantoin compounds
US4022878A (en) * 1972-05-15 1977-05-10 Biological Developments, Inc. Methods and compounds for producing specific antibodies
US3856469A (en) * 1973-01-02 1974-12-24 Syva Corp Interferant removal from amphetamine immunoassay
US3998943A (en) * 1973-10-02 1976-12-21 Syva Company Double receptor fluorescent immunoassay
US3979507A (en) * 1973-11-23 1976-09-07 Wilson Pharmaceutical & Chemical Corporation Diagnostic system for organ abnormalities
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
US3952091A (en) * 1974-10-23 1976-04-20 Hoffmann-La Roche Inc. Simultaneous multiple radioimmunoassay
US4036823A (en) * 1975-04-28 1977-07-19 Biological Developments, Inc. Barbituric acid antigenic conjugates, their preparation, antibodies and use
USRE32696E (en) * 1975-09-04 1988-06-14 Akzona Incorporated Enzymatic immunological method for determination of antigens and antibodies
US4101549A (en) * 1976-05-26 1978-07-18 Hoffmann-La Roche Inc. Aminophenyl esters of 5-carboxyalkyl barbituric acids
JPS5341420A (en) * 1976-09-29 1978-04-14 Mochida Pharm Co Ltd Immunochemically measuring methoa of hapten
US4816253A (en) * 1977-12-08 1989-03-28 Likhite Vilas V Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
US4567041A (en) * 1977-12-08 1986-01-28 Likhite Vilas V Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
WO1979000515A1 (en) * 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
US4347312A (en) * 1980-03-20 1982-08-31 Research Triangle Institute Detection of antibiotics in milk
US4645828A (en) 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
IE64785B1 (en) 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
US4721704A (en) * 1986-05-09 1988-01-26 Peninsula Laboratories, Inc. Potent synthetic atrial peptide analogs
US5099020A (en) * 1989-11-27 1992-03-24 Abbott Laboratories Barbiturate assay compositions and methods
CH678394A5 (OSRAM) * 1990-08-22 1991-09-13 Cerny Erich H
US6699474B1 (en) * 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
US5414085A (en) * 1992-04-06 1995-05-09 Biosite Diagnostics, Inc. Barbiturate derivatives and protein and polypeptide barbiturate derivative conjugates and labels
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
DE69630877T2 (de) * 1995-03-31 2004-11-11 Xenova Research Ltd., Slough Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US6696254B2 (en) 2001-11-21 2004-02-24 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
SI2508596T1 (sl) 2002-02-21 2016-01-29 Institute Of Virology Slovak Academy Of Sciences Monoklonska protitelesa, specifična za MN/CA IX, proizvedena iz MN/CA IX deficientnih miši, in postopki uporabe
DE60328477D1 (de) * 2002-04-16 2009-09-03 Univ California Verfahren zur prognose von nierenzellkarzinom und behandlungsauswahl mit carboanhydrase ix
EP1649282A4 (en) * 2003-07-07 2007-08-29 Webb Waring Inst PROCESS FOR PREDICTING THE DEVELOPMENT OF AUTOIMMUNE DISEASES AND TREATMENT THEREOF
KR101403910B1 (ko) 2003-11-04 2014-06-09 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 길항제 항-ｃｄ４０ 단클론성 항체 및 그것의 사용 방법
US20070098717A1 (en) 2003-11-04 2007-05-03 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
PL1684805T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40
US20070110754A1 (en) 2003-11-04 2007-05-17 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
US7022492B2 (en) * 2003-12-15 2006-04-04 Dade Behring Inc. Ecstasy haptens and immunogens
US6991911B2 (en) * 2003-12-15 2006-01-31 Dade Behring Inc. Assay for entactogens
US20050130243A1 (en) * 2003-12-15 2005-06-16 Zheng Yi F. Assay for entactogens
US7115383B2 (en) * 2004-03-22 2006-10-03 Dade Behring Inc. Assays for amphetamine and methamphetamine
US7037669B2 (en) * 2004-03-22 2006-05-02 Dade Behring Inc. Assays for amphetamine and methamphetamine using stereospecific reagents
US20090118132A1 (en) * 2004-11-04 2009-05-07 Roche Molecular Systems, Inc. Classification of Acute Myeloid Leukemia
US7842794B2 (en) 2004-12-17 2010-11-30 Roche Molecular Systems, Inc. Reagents and methods for detecting Neisseria gonorrhoeae
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
CN101426817B (zh) 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
EP3009449B1 (en) 2008-07-16 2018-06-06 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
AU2008359583B2 (en) 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
BRPI0911699B8 (pt) * 2008-07-25 2023-02-28 Inst Res Biomedicine vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
PL2828293T3 (pl) 2012-03-20 2018-03-30 Humabs Biomed S.A. Przeciwciała, które neutralizują RSV, MPV i PVM oraz ich zastosowania
CN113667013B (zh) 2013-10-02 2024-04-09 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
CA2954780A1 (en) 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
BR122020023406B1 (pt) 2014-11-18 2023-10-31 Institut Pasteur Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, moléculas de ácido nucleico, vetor, célula isolada, composição farmacêutica, usos dos mesmos, e kit de partes
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
WO2016207402A1 (en) 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
US20190015509A1 (en) 2016-01-13 2019-01-17 Medimmune, Llc Method of treating influenza a
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
CA3058979A1 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
EP4292659A3 (en) 2018-12-19 2024-03-20 Humabs Biomed SA Antibodies that neutralize hepatitis b virus and uses thereof
US20220380441A1 (en) 2019-08-29 2022-12-01 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
CN118465272B (zh) 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
IL299201A (en) 2020-06-24 2023-02-01 Vir Biotechnology Inc Transgenic hepatitis B virus neutralizing antibodies and their uses
US12492372B2 (en) 2020-11-24 2025-12-09 Monash University Induced stem cells
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
AU2022233857A1 (en) 2021-03-10 2023-09-14 Mabylon Ag Antibodies against tdp-43 and methods of using the same

Also Published As

Publication number Publication date
CA956889A (en) 1974-10-29
JPS5928864B2 (ja) 1984-07-16
US3766162A (en) 1973-10-16
GB1327545A (en) 1973-08-22
DE2202441A1 (de) 1973-03-01
DE2202441C3 (OSRAM) 1981-01-15
JPS4828623A (OSRAM) 1973-04-16

Similar Documents

Publication Publication Date Title
DE2202441C3 (OSRAM)
DE3854194T2 (de) Monoklonale antikörper gegen glykosyliertes albumin, hybride zellinien, die diese antikörper produzieren, sowie deren verwendung.
DE3785038T2 (de) Monoklonale antikoerper gegen nicht reduzierte, nicht enzymatisch glykolysierte proteine.
DE2805663C3 (OSRAM)
EP0013930B1 (de) Immunogen, Antikörper für ein Thymus-Hormon, markiertes Thymus-Hormon und Verfahren zur Bestimmung dieses Thymushormons
DE2804457A1 (de) Immunsuppressive mittel
DE2901218A1 (de) Ung von theophyllin
DE69132122T2 (de) Reinigung von cytokeratinfragmenten
DE2608096C2 (OSRAM)
DE3218312C2 (de) Monoklonale Antikörper, Hybridoma-Zellklone, Verfahren zu ihrer Herstellung und ihre Verwendung zur Erkennung von Brustkrebs und maligner Lymphogranulomatose
DE2716536C2 (de) Methadon-Antigene und Verfahren zur Herstellung dieser
DE60035267T2 (de) Verfahren zur analyse der menge an intraabdominalem fettgewebe
DE2310280A1 (de) Tubocurarin-antigene
DE2548196A1 (de) Antigene auf basis von methaqualon- hapten sowie deren verwendung
EP0124779A2 (de) Radioimmunverfahren für Thymosin beta 4
DE3887727T2 (de) Partikelstabilisierte Epitope zur Standardisierung und Kontrolle von Immuntests.
DE3025226A1 (de) Radioimmunoassay zur bestimmung von pterinen und neue dafuer verwendbare pterinderivate
DE3509958A1 (de) Monoklonale antikoerper gegen atriale, natriuretische peptide vom menschen
DE2738156A1 (de) Bestimmung von catecholaminen
DE2811003A1 (de) Immunverfahren zur bestimmung von beta-endorphin sowie antigen und antikoerper hierfuer
DE2126128A1 (de) Medizinisches Testverfahren, Reagens und Additiv zur Durchführung des Verfahrens
EP0420043B2 (de) Antikörper gegen hochkonservierte Aminosäuresequenzen von immunogenen Substanzen, Verfahren zur Herstellung dieser Antikörper, sowie deren Verwendung in Immunoassays
CH666490A5 (de) Verfahren zur herstellung von antikoerpern, die gegen insulin gerichtet sind und ihre verwendung.
DE69110067T2 (de) Monoklonale Antikörper gegen nicht-A 1C glykosyliertes Hämoglobin.
DE4008546A1 (de) Osteocalcin-spezifischer monoclonaler antikoerper

Legal Events

Date Code Title Description
OD Request for examination
C3 Grant after two publication steps (3rd publication)
8339 Ceased/non-payment of the annual fee